SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-080040
Filing Date
2024-07-02
Accepted
2024-07-02 09:16:28
Documents
15
Period of Report
2024-06-30
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K awh-20240630.htm   iXBRL 8-K 48425
2 EX-4.1 awh-ex4_1.htm EX-4.1 159350
3 EX-10.1 awh-ex10_1.htm EX-10.1 250870
4 EX-99.1 awh-ex99_1.htm EX-99.1 22246
5 GRAPHIC img245972787_0.jpg GRAPHIC 933834
  Complete submission text file 0000950170-24-080040.txt   1942953

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT awh-20240630.xsd EX-101.SCH 25815
17 EXTRACTED XBRL INSTANCE DOCUMENT awh-20240630_htm.xml XML 4896
Mailing Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738
Business Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738 512-519-0400
Aspira Women's Health Inc. (Filer) CIK: 0000926617 (see all company filings)

IRS No.: 330595156 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34810 | Film No.: 241093069
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)